ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...

MISTs for BPH focus on preserving sexual function and improving quality of life, with tailored treatment plans for individual needs. The Butterfly Prostatic Retraction Device, designed to fit the ...

In this video, part 4 of a 4-part series, panelists discuss how primary care providers can address patient questions on prostate cancer screening. In this Special Report from Urology Times®, Michael S ...

In this video, part 2 of a 4-part series, panelists discuss the increasing prevalence of de novo metastatic hormone-sensitive prostate cancer. In this Special Report from Urology Times®, Michael S.

Panelists discuss how they approach a typical bladder cancer case of a 79-year-old man with hematuria, including initial diagnostic procedures, the importance of proper tumor measurement during ...

Paul E. Dato, MD, discusses how patient-specific factors such as age, tumor volume, comorbidities, and treatment adherence are critical for therapy selection, emphasizing the importance of assessing ...

Paul E. Dato, MD, discusses how a 63-year-old Black man with recurrent hormone-sensitive prostate cancer (HSPC) presented with high-grade disease and multiple metastases after initial prostatectomy, ...